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Abstract
Many studies have shown that missense mutations might play an important role in carcinogenesis. However, the extent to
which cancer mutations might affect biomolecular interactions remains unclear. Here, we map glioblastoma missense
mutations on the human protein interactome, model the structures of affected protein complexes and decipher the effect
of mutations on protein-protein, protein-nucleic acid and protein-ion binding interfaces. Although some missense
mutations over-stabilize protein complexes, we found that the overall effect of mutations is destabilizing, mostly affecting
the electrostatic component of binding energy. We also showed that mutations on interfaces resulted in more drastic
changes of amino acid physico-chemical properties than mutations occurring outside the interfaces. Analysis of
glioblastoma mutations on interfaces allowed us to stratify cancer-related interactions, identify potential driver genes, and
propose two dozen additional cancer biomarkers, including those specific to functions of the nervous system. Such an
analysis also offered insight into the molecular mechanism of the phenotypic outcomes of mutations, including effects on
complex stability, activity, binding and turnover rate. As a result of mutated protein and gene network analysis, we
observed that interactions of proteins with mutations mapped on interfaces had higher bottleneck properties compared to
interactions with mutations elsewhere on the protein or unaffected interactions. Such observations suggest that genes with
mutations directly affecting protein binding properties are preferably located in central network positions and may
influence critical nodes and edges in signal transduction networks.
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Introduction
Most cancers are characterized by genomic instability which is
considered to be one of the important factors driving tumor
development [1]. These genetic perturbations potentially lead to
abnormal oncogene activation and/or tumor suppressor gene
inactivation. According to the concept of ‘‘oncogene addiction’’,
cancer cells depend on the activity of a single or a few oncogenes
for their proliferation and survival [2]. Altered activity of
oncogenes and tumor suppressors may be caused by gene
amplifications, enhanced or decreased transcription or translation.
At the same time, missense mutations might also play a very
important role in carcinogenesis [3]. While contributing signifi-
cantly to tumorigenesis, majority of mutations are considered
neutral (i.e. ‘‘passenger’’ mutations), and only a few are under
positive selection in cancer cells (i.e. ‘‘driver’’ mutations) [3,4].
Various methods have been applied to predict the deleterious
effects of mutations [5,6], to find positively selected mutants and to
distinguish driver from passenger mutations [7,8]. However, their
predictive power remains limited, largely depends on the level of
evolutionary conservation [9] and the background mutation rate
which is difficult to determine for each sample [10]. Moreover,
recent results suggest that a large majority of single nucleotide
variations predicted to be functionally important are rare (with
minor allele frequency less than 0.5%) [11], making such rare
disease-associated variants difficult to detect.
Many signaling networks are deregulated in cancer and involve
a dense network of protein-protein interactions. Therefore, the
characterization of cancer-related protein interaction networks is
essential for our understanding of the molecular mechanisms of
carcinogenesis. Recently, new strategies were proposed to identify
key network modules and driver oncogenes by combining copy
number variations, missense mutations and mapping potential
oncogenic driver genes onto high-throughput protein-protein
interaction networks [12,13,14]. As a result of these studies, novel
cancer-related genes and functionally-related gene modules
targeted by driver cancer mutations were identified [13,14,15].
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Moreover, proteins recognize and bind their specific targets in a
highly regular manner and the specificity of these interactions is
largely determined by structural and physico–chemical properties
of binding interfaces. Recently, structural complexes of disease-
and cancer-related proteins were analyzed [16,17,18,19], showing
that disease-related protein complexes have distinct binding
properties; in particular, they contain multiple interface patches,
enabling interactions with many other proteins [16], and
mutations on different patches might have caused pleiotropic
disease effects [20]. In addition, many disease mutations are
located on protein-protein interfaces [21,22,23], a tendency that is
especially pronounced for cancer missense mutations [20]. Such
observations generally emphasize the importance of studying the
effects of cancer mutations on protein interactions and on their
binding interfaces in particular.
Many oncogenes, tumor suppressors and their mutations have
been identified as key players in cancer signaling events. However,
only a few have been found in different types of cancer
simultaneously. Such heterogeneity complicates the identification
of key players that provide selective advantages to tumor cells. In
our study we utilized a set of mutations derived from glioblastoma
patients, allowing us to narrow down the heterogeneity of
phenotypic response to better understand genotype-phenotype
relationships. Glioblastoma is the most malignant form of brain
tumors according to WHO classification [24]. Recently, The
Cancer Genome Atlas (TCGA) and other projects provided
mutation data of glioblastoma patients on a large scale [25,26].
Eight potential driver genes were identified in glioblastomas, and
mapping mutated genes on biochemical pathways indicated
several prevalent pathways that contained mutated driver genes
[25,26,27]. Specifically, genome alterations that were found in
several key pathways were observed to be mutually exclusive to
each pathway, pointing to the sufficient selective advantage of
these few alterations for cancer cells [25].
Recently, we mapped the human protein interactome using
structural complexes which allowed us to decipher the effect of
glioblastoma missense mutations on protein-protein, protein-
nucleic acid, protein-ion binding interfaces and phosphorylation
sites in this study (Figure 1). Here, we show that mutations on
binding interfaces result in more drastic changes of amino acid
physico-chemical properties than mutations that cannot be
mapped on interfaces. Moreover, we found that mutations on
protein-protein interfaces have overall destabilizing effects and
mostly affect the electrostatic component of binding energy as well
as the topology of protein-protein interaction networks. Impor-
tantly, we identify possible driver mutations and genes, some of
which are specific to nervous system functioning. We complement
our findings by suggesting the molecular mechanisms of the
phenotypic effect of mutations.
Results and Discussion
Cancer Mutations might Affect Phosphorylation Sites
Many proteins that play an important role in cancer may also
participate in signaling pathways, typically mediating signals
through phosphorylation events. Previously, somatic cancer
mutations were shown to potentially cause gain or loss of
phosphorylation sites [29]. Therefore, we hypothesized that
glioblastoma mutations may also affect phosphorylation sites,
potentially disrupting the flow of signals through the loss of sites.
We collected 2,825 phosphorylation sites from the PhosphoSite-
Plus [30], Phospho.ELM [31] and PHOSIDA [32] databases
which were further verified by GPS software [33]. While 94
mutation sites in Ser/Thr/Tyr residues could be potentially
phosphorylated, we found that 6 out of 94 sites significantly
overlapped with phosphorylation sites (Fisher exact test p-
value = 0.028, Table S1 in File S1). Indeed, phosphorylation
may be accompanied by the changes in local site environment or
global conformation, lead to protein activation or inactivation and
modulate the strength of protein or DNA interactions [34].
Therefore, mutation of a phosphorylation site may result in the
loss of these important functional properties, as exemplified by the
loss of phosphorylation site Ser 313 in P53 that regulates binding
to DNA.
Effect of Glioblastoma Mutations on Protein Binding
We integrated mutated genes in a structurally inferred protein
interaction network and estimated the effect of these mutations on
such a network. Specifically, we constructed mutant structural
models (see Methods) and calculated the differences of binding
energies that were caused by the corresponding amino acid
substitutions. We found a negative average binding energy
difference of DDDG=22.54 kcal/mol, pointing to an overall
destabilizing effect of mutations on protein-protein complexes in
glioblastomas (Figure 2A, Table 1). Furthermore, the electrostatic
component of binding energy was shifted towards negative values
compared to zero (p-value = 0.007) and compared to the van-der-
Waals component (p-value = 0.0013). Meanwhile, the van-der-
Waals component itself did not show an overall de- or over-
stabilizing effect. While several applications have been developed
to predict the effect of mutations on protein stability, we compared
our results to FoldX, allowing us to observe a significant, although
not very high, correlation between the DDDG values of both
approaches (Figure S1B in File S1, Pearson’s rP = 0.440.77, p-
value,0.01). These differences may arise from the fact that FoldX
uses an empirical potential calibrated on the set of experimental
changes of unfolding energy in the presence of mutations.
Furthermore, FoldX is not explicitly trained on disease mutations
and binding energy changes and does not account for the
mutation induced conformational changes of the protein back-
bone.
In general, substitutions with amino acids that have similar
physico-chemical properties may not drastically alter the stability
of a single protein or a complex. We calculated physico-chemical
distances between wild-type and substituted residues and com-
pared it with the binding energy difference for all protein
complexes and their models (see Methods). The physico-chemical
distance was defined as the Euclidean distance using ten different
physico-chemical properties of amino acids [28]. As indicated by
its corresponding DDDG, the effect of substitutions was statistically
significantly correlated with the physico-chemical distance (Figure
S1B in File S1, Pearson rP =20.50, p-value = 0.015). Specifically,
large distances corresponded to large negative DDDG and vice versa,
suggesting that substitutions of amino acids with very different
properties are usually destabilizing. In turn, small changes in
amino acid properties may result in additional stabilization of
complexes. All the data about physico-chemical distances and
effects on binding energy are available at ftp://ftp.ncbi.nih.gov/
pub/panch/GBM/.
Such results also prompted us to estimate the potential
amplitude of the effect of mutations even if structures or models
were unavailable. Therefore, we calculated physico-chemical
distances for all 695 mutations from 598 genes. We observed that
distributions of physico-chemical distances that referred to amino
acid substitutions on all types of interfaces, and protein-protein
interfaces in particular, had significantly larger distances compared
to non-interface regions (Figure 2B, p-value = 0.011, Wilcoxon
test). For example, we observed that the first peak in Figure 2B
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Figure 1. Mapping the human interactome and glioblastoma mutations on binding interfaces. In step 1 we mapped 695 missense
mutations from 598 human genes to protein sequences. Subsequently, query protein sequences were aligned to homologous, experimentally
determined structural complexes (step 2), allowing us to infer query-specific interactions with other proteins, nucleic acids and ions (step 3). For
Cancer Mutations, Protein Binding and Networks
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around 0.5 mostly referred to substitutions of aliphatic residues
into each other or aliphatic into polar residues with Val-.Met
being the most frequent. The substitutions of arginine and cysteine
were among the most frequent, had physico-chemical distances of
about 141.5 and corresponded to the second peak of the
distribution in Figure 2B. In addition, we found that mutations
often affected arginine on binding interfaces. Arginine has unique
binding properties originating from strong stabilization of its
protonated form due to its high pKa. Furthermore, Arg forms salt
bridges, strong cation-p interactions and is enriched in binding hot
spots [35,36,37].
Interface Analysis Complements Machine-learning
Methods and Helps to Decipher Molecular Mechanisms
Several machine-learning methods were recently developed to
predict the phenotypic effect of disease mutations on proteins and
were successfully used for monogenic diseases [5,6]. Most of these
methods utilize evolutionary conservation, residue mutability and
accessible surface area as their main predictive features. We
predicted the effect for 581 glioblastoma mutations using
PolyPhen2, performing quite well in comparison to other
prediction methods [38]. Our results showed that PolyPhen
predicted 69% of all mutations on interfaces as ‘‘probably
damaging’’ (Table S2 in File S1, tables at ftp://ftp.ncbi.nih.gov/
pub/panch/GBM/). Such an agreement is noteworthy, given that
our protocol is not trained on a known set of disease mutations
while methods like PolyPhen do not use interface features in their
training. Interestingly, we also found a limited but still significant
correlation between the largest absolute value of the energetic
effect of mutations on protein binding DDDG (as obtained by our
approach) and the corresponding PolyPhen2 score (Spearman
rank correlation, rS = 0.5, p-value = 0.03). Since 23% of all
mutations that PolyPhen predicted as ‘‘probably damaging’’ were
located on interfaces, our approach may suggest the possible
mechanism of their damaging effect through their impact on
protein interactions.
As previously noted, many machine learning methods assessing
the effects of mutations erroneously predict a ‘benign’ effect when
the mutation occurs in an evolutionarily non-conserved position or
is solvent accessible [9]. Yet, when a protein complex is formed, a
mutation which was previously solvent accessible in a monomer
(and possibly non-conserved) may be buried on the binding
interface and very damaging for protein interactions. We show
that 18% of interface mutations were predicted by Polyphen2 as
‘‘benign’’; we analyze their possible driver effect and mechanism of
action in the next two sections. Therefore, the necessity to develop
approaches which complement machine learning methods with
more detailed biophysical analyses is evident and should be the
subject of future endeavors.
Mechanisms of Effects of Mutations on Protein-protein
Interactions
Here, we analyze the effect of mutations on protein-protein
complexes and suggest the underlying mechanisms which include
inactivation of wild-type enzymatic activity, destabilization of a
functional multimeric complex and alteration of the protein
turnover rate. All analyzed mutations were predicted to be benign
by PolyPhen2. The first case represents the IDH1 R132H
mutation potentially inactivating the wild type conversion of
isocitrate to a-ketoglutarate (a-KG) and/or resulting in a neo-
enzymatic activity and production of D-2-hydroxyglutarate [39].
Since IDH1 mutations are heterozygous we first analyzed the
heterodimer containing one mutated and one wild type chain.
Specifically, we found that heterodimers in the inactive state of
IDH1 (PDB code 1T09) were considerably stabilized by 8.6 kcal/
mol. In addition, we performed calculations for a double mutant
where both chains contained the R132H mutation, and showed
that its inactive dimer is further stabilized by 11.3 kcal/mol. Our
results are consistent with former studies suggesting that IDH1
heterodimers are stable with a considerably lowered isocitrate
dehydrogenase activity while R132H:R132H homodimers were
almost completely inactive [40]. In accordance with other
experimental studies, we suggest that such inactive dimer over-
stabilization might prevent the conformational cooperative move-
ments of dimer subunits required to form the active state [41].
Neuroligins (NLs) are transmembrane proteins on the postsyn-
aptic cell surface and serve as receptors for neurexins that are
synaptic cell adhesion proteins on the presynaptic cell surface.
Since the formation of proper synapses is crucial for normal brain
function we investigated the model of neuroligin2 (NLGN2) based
protein-protein interactions, we mapped interaction partners to their corresponding human proteins (step 4a), allowing us to find 160 protein
interactions between 150 genes with mutations affecting their interaction interfaces. In step 4b, we compared the structures of the unperturbed
wild-type protein and the mutated protein by performing energy minimization calculations and determining binding energy differences.
doi:10.1371/journal.pone.0066273.g001
Figure 2. The effect of mutations on protein binding. (A) Distribution of binding energy difference upon mutation for electrostatic and van-
der-Waals components. The electrostatic component of binding energy was significantly shifted toward negative values compared to the van-der-
Waals component (p-value = 1.361023) (B) Distributions of physico-chemical distances between amino acids that correspond to glioblastoma
mutations on protein-protein interfaces and non-interface regions. Distributions that referred to amino acid substitutions on protein-protein
interfaces had significantly larger distances compared to non-interface regions (p-value= 0.011).
doi:10.1371/journal.pone.0066273.g002
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on the neuroligin-1/neurexin-1 beta complex [42] (PDB code
3BIW, 75% identity between NLGN2 and structural template).
Earlier it was determined that the synaptogenic activity strongly
depended on the formation of stable neuroligin-1 multimers [43].
We observed that glioblastoma mutation E577K was located on
Table 1. List of representative genes with mutation sites located on different types of protein binding interfaces.




binding partner Dist. Phys dddG
Protein-protein
ABL2 6382062 P 487 L 2RF9_A 2RF9_C 1.17 0.695
EPHA2 32967311 G 111 D 3MBW_A 3MBW_B 1.28 0.14
IDH1 28178825 R 132 H 1T09_A 1T09_B 1.03 8.64
NLGN2 30840978 E 577 K 3BIW_A 3BIW_D 1.54 21.24
NRAS 4505451 G 12 D 1NVU_R 1NVU_S 1.28 24.24
RAB3C 19923985 R 49 H 2P5S_B 2P5S_A 1.03 21.48
RAC2 4506381 D 47 Y 2V55_B 2V55_A 1.40 22.14
RAD52 109637798 R 46 K 1KN0_A 1KN0_K 0.57 9.04
TP53 120407068 P 177 S 1YCS_A 1YCS_B 1.19 21.29
TP53 120407068 R 248 Q,W 1YCS_A 1YCS_B 1.14,1.75 224.31, 229.69
TP53 120407068 R 273 H,C 1YCS_A 1YCS_B 1.03,1.78 23.44, 213.45
TP53 120407068 D 281 A 1YCS_A 1YCS_B 1.16 9.03
Protein-DNA
BCL11A 20336305 R 740 C 2DRP_A DNA 1.78 20.02
PAX9 7242167 R 26 W 6PAX_A DNA 1.75 20.05
TP53 120407068 R 248 Q,W 3KMD_A DNA 1.14,1.75 0.36, 1.27
TP53 120407068 R 273 H,C 3KMD_A DNA 1.03,1.78 20.84, 20.54
TP53 120407068 A 276 V 3KMD_A DNA 0.573 0.28
ZIK1 77736604 T 393 A 2I13_A DNA 0.55 20.40
ZNF339 40807463 T 222 M 1MEY_C DNA 0.81 20.11
Protein-RNA
ELAVL2 115511032 G 167 D 1FXL_A RNA 1.28 –
KLK9 29366812 Y 240 D 3DD2_H RNA 1.40 –
RBMS3 51317353 I 166 V 1FXL_A RNA 0.42 –
RPL11 15431290 R 75 X 3KCR_F RNA - –
Protein-ion
ADAMTS17 110611170 D 434 G 1KUG_A Cd2+ 1.28 –
DSG4 29789445 V 262 I 3Q2V_B Ca2+ 0.42 0.00
GZMH 15529990 V 207 M 1XXF_B Na+ 0.41 0.11
HPCAL4 7705419 P 10 H 1G8I_B Na+ 1.17 0.00
LCT 32481206 V 565 E 2ZOX_A Mg2+ 1.27 2.72
LMX1A 28893581 C 62 Y 2XJY_A Zn2+ 0.82 23.23
MAPK9 21237736 G 35 R 1JNK_A Mg2+ 2.02 21.06, 21.38
NELL2 5453766 D 602 N 1UZJ_B Ca2+ 0.78 0.27
SGK2 20127541 R 152 G 3KGA_A Mg2+ 2.02 0.01
TP53 120407068 C 176 Y,F 1TSR_A Zn2+ 0.82,0.61 24.72, 24.67
TP53 120407068 H 178 Q 1TSR_A Zn2+ 0.732 0.00
TP53 120407068 H 179 Y 1TSR_A Zn2+ 1.037 25.25
ZIK1 77736604 T 393 A 1MEY_G Zn2+ 0.55 0.60
ZNF497 333033771 D 278 N 1U85_A Zn2+ 0.78 20.02
ZNF497 333033771 Q 433 L 1NJQ_A Zn2+ 1.26 20.84
Gene and protein identifiers are shown together with the PDB code of structural evidence of interactions (structure of homologous complex), physico-chemical
distances between substituted amino scids (‘‘Dist Phys’’) and difference in binding energy (‘‘dddG’’). Several multiple substitutions of the same site are listed on the
same line.
doi:10.1371/journal.pone.0066273.t001
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the dimer interface of two neuroligin monomers and contributed
to a destabilization of this dimer by 1.2 kcal/mol [43].
The third example represents Rad52 playing a critical role in
DNA double-strand-break repair. This protein is characterized by
a very rapid turnover that is tightly regulated in the cell.
Specifically, we observed that mutation R46K was located on
the multimeric interface in the model of RAD52 N-terminal half of
the protein (pdb code 1KN0) and considerably over-stabilized
each dimer in the undecameric complex by 9 kcal/mol. Such a
result might suggest that this mutation may considerably affect the
Rad52 turnover rate. Indeed, it was previously shown that some
mutants extend the half-life of Rad52 and dysregulate their
turnover in a cell [44].
Mechanisms of Effects of Mutations on Protein-nucleic
Acid and Protein-ion Interfaces
Other than protein-protein interactions, cancer mutations may
affect other types of protein interactions as well. Altogether we
found 16 and 13 mutations mapped to protein-ion and protein-
nucleic acid binding interfaces, respectively. Table 1 shows
representative examples with mutations located on binding
interfaces and lists candidates for cancer biomarkers. As indicated
in Table 1, mutations on five genes that correspond to protein-
DNA or protein-ion interactions (BCL11A, ZIK1, ZNF497,
ZNF339, and TP53) are located within C2H2-type zinc finger
motifs. The zinc ion is essential for the stabilization of the local
structure required for DNA binding. The disruption of Zn ion
coordination may potentially lead to deregulation of correspond-
ing proteins. Specifically, we found a C62Y substitution in LIM
homeobox transcription factor 1 alpha (LMX1A), an important
factor for the development of the nervous system. This transcrip-
tion factor harbors two LIM zinc-binding domains, and the C62Y
substitution occurs at one of the zinc-binding cysteine residues in
the structure of its homolog LMO-2 and leads to decreased Zn-
binding by 3.2 kcal/mol (see tables on ftp site) (Figure 3A). Indeed,
a recent study suggested that LMX1A might play a tumor
suppressive role and may be targeted for therapeutic intervention
in human [45].
Paired box protein PAX9 is another example originating from
the transcription factor Pax family that regulates the expression of
target genes involved in proliferation, stem-cell self-renewal,
resistance to apoptosis and cell migration. PAX9 expression is
associated with favorable outcome in several cancers although its
role in tumorigenesis is not well understood [46]. We studied the
substitution R26W which, according to the crystal structure of its
homolog PAX6 (75% identical to PAX9), directly interacts with the
DNA molecule [47] (Figure 3B). Although the substitution with
tryptophan may have rather drastic consequences for the
maintenance of the networks of electrostatic interactions between
arginine and DNA phosphates, we did not find considerable
differences in protein-DNA binding affinity (DDDG= –0.05 kcal/
mol) although the mutation destabilizes an overall complex by
2.15 kcal/mol.
Cancer mutations may also directly affect enzymatic activity.
Being involved in proliferation, differentiation and apoptosis
pathways, mitogen-activated protein kinase 9 (MAPK9) blocks
the ubiquitination of tumor suppressor p53 leading to an increase
of suppressor stability. Similar to other phosphate transferring
enzymes, MAPK9 uses magnesium as a cofactor for phosphory-
lation. We studied G35R substitution in MAPK9 and hypothesized
that it might disrupt its tumor suppressor properties. The crystal
structure of its homolog MAPK10 (with 85% sequence identity to
MAPK9) shows that Gly35 is located at the edge of the ATP
binding pocket and participates in an ATP-binding loop [48].
According to FoldX calculations the substitution of glycine into
positively charged arginine compromises magnesium cation
binding by 1.38 kcal/mol, supporting the deregulation of MAPK9
kinase activity and cancer cell development (Figure 3C).
Properties of Mutated Interaction Network
Topological network analysis facilitates the interpretation of
interaction data and may allow the inference of cellular functions
from the underlying proteins [49]. By mapping mutations and
corresponding substitutions on protein-protein interfaces using our
IBIS structural inference approach [50,51], we identified 160
protein-protein interactions between 150 proteins with mutations
that were located directly on binding interfaces (‘‘mutant
interactions’’, MI). Furthermore, we embedded these interactions
in a web of 4,073 interactions between 2,928 human proteins
where each interaction was obtained by high-throughput methods
as well as confirmed by the IBIS structural inference approach. In
such a ‘confirmed interaction network’ we considered interactions
that involved a protein with a mutation anywhere in a protein,
allowing us to collect 444 ‘‘all mutant interactions’’ (AI).
Therefore, the set of MI interactions is a subset of the AI set.
To determine the role that ‘‘MI’’ and ‘‘AI’’ interactions play in a
large human interaction network we determined the topological
characteristics of such affected interaction networks. While we
observed that the confirmed interaction network breaks into many
connected components, we carried out our topological investiga-
tions on the largest connected component of 1,960 interactions
(Figure 4A).
Figure 3. Examples of mutations on protein-nucleic acid and protein-ion interactions. Residues at mutated sites on homologous proteins
are shown in red (wild type) and blue (mutant) stick models. (A) Zinc binding motif of LMO-2, homologous protein of LMX1A (PDB: 2XJY chain A,
sequence identity 35%). A zinc ion is shown as a dark blue sphere. Zinc binding residues are shown in yellow stick models. (B) DNA binding site of
Pax-6, homolog of Pax-9 (PDB: 6PAX chain A, sequence identity: 74%). (C)MAPK10, homolog of MAPK9, with Mg-ANP (ATP analog) (PDB: 1JNK chain A,
sequence identity: 85%). Mg ions are shown as green spheres and ANP is shown using a white sphere representation.
doi:10.1371/journal.pone.0066273.g003
Cancer Mutations, Protein Binding and Networks
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As a measure of clustering around a given interaction, we
defined the edge clustering coefficient [52]. Assuming that MI
interactions play a critical role in the flow of biological information
in an interaction network, we hypothesized that such interactions
may not be necessarily clustered but tend to bridge clustered areas.
Indeed, we observed that MI and AI interactions generally tend to
be placed in less clustered areas compared to the remaining
unaffected interactions in Figure 4B (Wilcoxon test, p-val-
ue = 561028). Notably, we also observed a significant shift to
lower clustering of MI interactions compared to AI interactions (p-
value = 0.01). A measure of an interaction’s centrality in a network
is its edge betweenness centrality. Specifically, edge betweenness
centrality determines the number of shortest paths through a given
edge, therefore corresponding to potential ‘‘bottlenecks’’. In the
inset of Figure 4B, we show that interactions between proteins with
mutations on binding interfaces (MI) had a significantly higher
betweenness centrality than interactions involving non-mutant
proteins (p-value = 0.005). We also found that such interactions
had significantly higher betweenness than interactions between
mutant proteins where mutation did not necessarily affect the
binding interface (AI) (p-value = 0.01).
Conclusions
Many studies have shown that missense mutations might play a
very important role in causing different diseases. However, causal
variants and phenotypic effects of these mutations are very difficult
to predict, especially for polygenic diseases [53]. Although
mutations of monogenic diseases might prefer the core of the
protein [54], cancer related mutations exhibit quite a different
pattern. Specifically, such mutations are less likely to occur in the
protein core and prefer binding interfaces [20,23]. Nevertheless
the extent to which mutations might affect biomolecular interac-
tions remains largely unknown. With this goal in mind we
addressed the molecular mechanism of carcinogenic effects of
glioblastoma mutations. The actual placement of cancer mutations
on binding interfaces allowed us to stratify cancer-related
interactions and potential driver genes and address the ways such
mutations may affect binding and the underlying protein
interaction network’s topology.
First, we found that overall missense mutations had a
significantly destabilizing effect on protein-protein interactions
although some mutations over-stabilized protein complexes. This
effect was mostly driven by the electrostatic component of binding
energy and such observations are consistent with previous
investigations, focusing on the effects of OMIM mutations on
protein complexes [22]. Indeed, the charge complementarity may
determine specific binding while its disruption can be accompa-
nied by the loss of specific interactions. The contribution of a given
charged pair of amino acids to the electrostatic component of
binding energy depends on the balance of two large terms:
desolvation penalty and electrostatic pairwise interactions. While
the desolvation penalty of a group mostly depends on its net
charge, the pairwise electrostatic interaction energy is also sensitive
to the geometry of the side chains. Previous results indicated that
electrostatic interactions on protein-protein binding interfaces are
almost always favorable [55]. Therefore, amino acid substitutions
might result in dramatic changes of the magnitude of the favorable
pairwise electrostatic interactions, while having little impact on the
desolvation penalty [56].
Furthermore, we calculated changes in physico-chemical
properties between wild-type and substituted residues and found
that amino acid substitutions on binding interfaces were associated
with significantly larger physico-chemical distances compared to
non-interface mutations. The most drastic amino acid changes
were observed for mutations on protein-protein binding interfaces.
Such observations point to the possible damaging effect of many
glioblastoma mutations on interfaces. We expect that such
mutations are unlikely passenger mutations but rather may drive
the disease phenotype. Such an argument appears plausible given
that genetic alterations in cancer generally affect signaling
pathways, compromising many protein-protein interaction events.
Specifically, we detected a group of potential cancer biomarkers,
some of them specific to nervous system development, which
Figure 4. Network analysis of protein interactions that are affected by mutations. (A) By mapping all structurally inferred interactions that
suffer from a mutation on their interfaces in a human interaction network (MI) we obtained a largest component capturing 1,960 interactions.
Furthermore, we indicated all interactions that involved a mutated protein (AI). (B) Calculating edge clustering of MI and AI interactions in the largest
component, we observed that interactions affected by a mutation generally tend to appear in less clustered areas. Compared to the remaining
interactions, such differences were significant for both MI and AI interactions (p-value = 561028, Wilcoxon test). Comparing MI and AI interactions, we
observed a significant shift of MI interactions toward lower clustering (p-value= 0.01). In the inset, we determined edge betweenness of MI and AI
interactions as a measure of their centrality in the network. Compared to the remaining interactions, we found that differences between both sets of
interactions affected by mutations were statistically significant (p-value= 561023). Furthermore, MI showed significantly lower betweenness than AI
interactions (p-value= 0.01).
doi:10.1371/journal.pone.0066273.g004
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might be deregulated by mutations affecting protein-protein,
protein-nucleic acid and protein-ion binding.
Since many factors influence the topology of protein interaction
networks and the role of a given protein in cancer development, a
debate about the topological properties of disease and cancer-
related networks has emerged. Although the vast majority of
disease genes were found to be nonessential and did not encode
hub proteins, cancer related genes, however, suggested an opposite
trend [16,57,58]. High betweenness of proteins that translates into
being a ‘‘bottleneck’’ indicated another important characteristic
that distinguished essential and non-essential genes especially in
regulatory networks [59]. Hub-bottlenecks, for example, defined
as frequently interacting proteins connecting different clustered
areas, were indicated as good predictors of gene essentiality [16].
Here we found that interactions involving proteins with mutations
generally tend to occur in less clustered areas and are character-
ized by higher edge betweenness compared to the remaining
unaffected interactions from the same network. Importantly, we
also show that our stratification of cancer-relevant interactions had
a significant impact by focusing on glioblastoma mutations
observed directly on binding interfaces (MI). In particular, MI
interactions were placed in areas of lower clustering and higher
edge betweenness compared to AI interactions that did not
account for the mutated position with respect to protein binding.
Still, AI interactions had higher bottleneck properties compared to
the remaining, unaffected interactions.
Indeed, although oncogenes were reported to have a certain
tendency to cluster into a small number of modules and pathways
[60,61], other reports did not confirm such characteristics [16].
Here, we show that genes with mutations affecting their binding
interfaces were preferably located in central network positions
which might influence critical nodes/edges in signal transduction
networks mediated by protein-protein interactions. Our observa-
tion is consistent with two previous studies, indicating that proteins
extensively involved in signal transduction activity, actively
sending and receiving signals, are more frequently mutated in
cancer [60].
Materials and Methods
Constructing Human Interactome and Mapping
Mutations on Binding Interfaces
We used our recently developed framework to map the human
interactome [18]. Selecting the longest protein isoforms of a
human query sequence, we retrieved their protein interaction
partners and binding sites using the IBIS server (http://www.ncbi.
nlm.nih.gov/Structure/ibis/ibis.cgi) [50,51]. IBIS predicts protein
interaction partners and provides the locations of their binding
sites on a query protein using a set of homologous structural
complexes as evidence of an interaction. Along with different types
of protein interaction partners (protein, ion, DNA, RNA, peptide,
and small molecule), IBIS ensures the biological relevance of
binding sites. Utilizing structural complexes, IBIS collects
experimentally ‘observed’ protein interactions if a protein has a
certain number of residues that ‘contact’ its partner. Two residues
are considered to be in contact if any of the heavy-atom inter-
atomic distances is less than 6 A˚ for protein-protein (4 A˚ for
protein-nucleic acid and 3 A˚ for protein-ion) interaction partners.
Such a group of residues that is in contact to an interaction partner
is called a ‘‘binding site’’. Demanding that the sequence similarity
between the query protein and a homologous structural complex is
high enough (see Supporting Information for details), homologous
complexes were subsequently grouped according to their binding
site similarity. In the case of protein-protein interactions we
mapped interaction partners from complexes of other organisms to
their most similar human proteins that had more than 80%
sequence identity and 80% protein sequence coverage. As a result
of this procedure we obtained 54,861 protein-protein interactions
between 9,265 human proteins, a network we refer to as
‘structurally inferred’. In addition, we used IBIS to determine
protein-nucleic acids and protein-ion interactions, procedures that
did not require additional mapping of the interactions partners to
human proteins.
We also pooled 61,240 interactions between 11,446 proteins
from high-throughput experiments found in Reactome [62],
MINT [63] and HPRD [64]. We confirmed these interactions
by using structurally inferred interactions, allowing us to obtain
4,073 interactions between 2,928 human proteins, a network that
we refer to as the ‘‘confirmed interaction network’’. We compiled
missense mutations from genes in glioblastoma multiform patients
from two previous studies [25,26] that identified mutations in the
tumor sequences that were not present in the reference sequences
of each gene. Mutations present in the normal control samples and
in single nucleotide polymorphism (SNP) databases were then
removed from further analyses. We additionally verified interac-
tion interfaces in complexes using the PISA algorithm. Using
chemical thermodynamics, PISA computes a set of macromolec-
ular assemblies that are expected to be stable in solution and are
assumed to represent the biological form of a protein in the cell
[65]. In the end, we mapped 695 missense mutations from 598
genes on different types of proteins and protein binding interfaces
as shown in Figure 1. Altogether 97 mutations from 68 genes were
mapped on protein-protein interfaces affecting 160 protein-protein
interactions, whereas 16 and 13 mutations were found on protein-
ion and protein-nucleic acid interfaces respectively (ftp://ftp.ncbi.
nih.gov/pub/panch/GBM/). Among those mutations mapped on
interfaces, 33% mutations were observed in more than one cancer
sample according to the COSMIC database [66] compared to
15% of mutations which could not be mapped on interfaces.
Modeling of Protein Complexes
Based on templates identified in IBIS we built 3D structural
models of protein-protein complexes using a homology modeling
approach. In particular, we applied the Profix and Nest programs
provided by the Jackal package [67] to fix missing atoms or
residues of the templates and to build homology models of
complexes based on their sequence alignments. The models were
submitted to the TINKER package for energy minimization
utilizing the Limited Memory BFGS Quasi-Newton Optimization
algorithm [68]. Energy minimization was performed with the
Amber98 force field. The convergence criterion was set to the root
mean-squared (RMS) gradient per atom = 0.01. The Scap
program [69] as provided by the Jackal package was applied to
computationally generate the corresponding mutant structures
using the minimized wild-type models, and the mutations were
introduced by side-chain replacements. The wild-type and mutant
structures were minimized again using TINKER to assure that
both structures were subjected to the same refinement protocol
after introducing the mutation. It was previously shown that state-
of-the-art algorithms can always build high-quality models for
proteins with sequence identity higher than 35,40% to the
homologous protein structures [70]. Checking the quality of the
models, we removed models with large van-der-Waals clashes
based on calculated energies and selected only those models that
were based on protein-protein structural complexes with more
than 40% identity to both the query human protein and its
interaction partner which resulted in 21 high quality models of
protein-protein complexes. Protein-DNA and protein-ion com-
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plexes were modeled using Modeller [71] ‘‘automodel’’ function.
Mutations were introduced using FoldX ‘‘buildmodel’’ module.
DNA molecules were treated as non-flexible during the modeling
processes.
Binding Energy Calculation
Binding energy was calculated using the rigid body approach
described in previous studies [22,72,73]. We assumed that the
internal mechanical energies of the (un-)bound monomers remain
unchanged so that the energy terms of the unfolded state can be
excluded in the binding energy calculation. The total potential
energy and its two components, van der Waals energy and
electrostatic energy, for protein-protein complexes were computed
with the ANALYZE program as provided by the TINKER
package [68]. The electrostatic component of total potential
energy was defined as the sum of charge-charge interaction energy
and continuum solvation energy obtained from the TINKER
results. The binding energy was defined as the difference between
the potential energy of the dimer and the individual monomers.
DDG(binding)~DG(folding : complex){DG(folding : A)
{DG(folding : B)
ð1Þ
where DG(folding: complex), DG(folding: A) and DG(folding: B) were the
potential energies of the dimer complex, monomer A and
monomer B, respectively.
The effect of a mutation on binding affinity was assessed by
using the binding energy difference between the wild-type (WT)




where DDG(binding: WT) and DDG(binding: MU) were the
binding energies of the wild-type (WT) complex and the mutant
complex (MU) calculated using equation (1). The difference of
total potential energy (DDDGtot), van der Waals energy (DDDGvdW)
and electrostatic energy (DDDGel) were calculated and analyzed
separately. A negative value of DDDG binding indicated that the
mutation decreased the binding affinity, destabilizing the complex.
In turn, a positive value of DDDG binding suggested that the mutation
stabilized the complex.
We also used the ‘‘AnalyseComplex’’ function of the FoldX
program [74] which calculates the stability of protein complexes
using an empirical force field to estimate the effect of mutations on
binding. The change in binding energy was approximated by
impairing the selected targets, determining the stability of the
separated molecules and then subtracting the sum of the individual
energies from the global energy of the complex. Binding energy
differences for protein-DNA interactions were calculated similarly.
In these cases DG(folding: complex) refers to the stability of the
protein-DNA complex and DG(folding: A) refers to the stability of
the monomer without DNA. Binding energy of protein-ion
interactions were calculated by ‘‘MetalBindingEnergy’’ function
of FoldX. The best five models (with the highest Modeller molpdf
score) were analyzed and the mean values of DDDG calculated. All
protein-DNA and protein-ion models were preprocessed by the
RepairPDB function of FoldX before any energy calculation to
optimize side chain conformation.
Topological Measures of Interaction Networks
As a global measure of a protein-protein interaction’s centrality,
we calculated edge betweenness, reflecting an edge’s appearance
in shortest paths through the whole network. In particular, we





s(s,t) . s(s,t) was the number of shortest paths between
proteins s and t while s(s,t|v) was the number of shortest paths




where N was the number of proteins
in the connected component in which the underlying edge
appeared. The edge clustering coefficient of interacting proteins
i and j was defined as ECij~
DNi\Nj D
min (DNi D{1,DNj D{1)
, where Ni and Nj
were the sets of interaction partners of i and j, respectively [52].
Statistical Analysis
To perform statistical tests we used Splus and R packages. To
compare mean values of two distributions (or compare the mean
value to zero), we used the Wilcoxon rank test and reported one-
sided p-values. To test the independence between the rows and
columns in a contingency table, we used Fisher’s exact test and
reported two-sided p-values. We also calculated Pearson and
Spearman correlation coefficients to test the null hypothesis about
the independence of two variables and reported two-sided p-
values.
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sites), Table S2 (Prediction of the effect of mutations on protein-
protein and non-interface regions using PolyPhen2), Figure S1
(The change of binding energy) and Text S1 (Mapping of
complete interactomes using structural complexes, methodology).
(DOCX)
Author Contributions
Conceived and designed the experiments: AP SW. Performed the
experiments: HN MT ST EA SW AP. Analyzed the data: HN MT ST
EA SW AP. Contributed reagents/materials/analysis tools: BS KH. Wrote
the paper: AP SW HN MT ST EA.
References
1. Loeb LA (1991) Mutator phenotype may be required for multistage
carcinogenesis. Cancer Res 51: 3075–3079.
2. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68: 3077–3080;
discussion 3080.
3. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic
landscapes of human breast and colorectal cancers. Science 318: 1108–1113.
4. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007)
Patterns of somatic mutation in human cancer genomes. Nature 446: 153–158.
5. Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect
protein function. Nucleic Acids Res 31: 3812–3814.
6. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010)
A method and server for predicting damaging missense mutations. Nat Methods
7: 248–249.
7. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic
mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069–1075.
8. Youn A, Simon R (2011) Identifying cancer driver genes in tumor genome
sequencing studies. Bioinformatics 27: 175–181.
9. Kumar S, Suleski MP, Markov GJ, Lawrence S, Marco A, et al. (2009)
Positional conservation and amino acids shape the correct diagnosis and
population frequencies of benign and damaging personal amino acid mutations.
Genome Res 19: 1562–1569.
10. Torkamani A, Verkhivker G, Schork NJ (2009) Cancer driver mutations in
protein kinase genes. Cancer Lett 281: 117–127.
11. Tennessen JA, Bigham AW, O’Connor TD, Fu W, Kenny EE, et al. (2012)
Evolution and functional impact of rare coding variation from deep sequencing
of human exomes. Science 337: 64–69.
Cancer Mutations, Protein Binding and Networks
PLOS ONE | www.plosone.org 9 June 2013 | Volume 8 | Issue 6 | e66273
12. Cerami E, Demir E, Schultz N, Taylor BS, Sander C (2010) Automated network
analysis identifies core pathways in glioblastoma. PLoS One 5: e8918.
13. Hosur R, Xu J, Bienkowska J, Berger B (2011) iWRAP: An interface threading
approach with application to prediction of cancer-related protein-protein
interactions. J Mol Biol 405: 1295–1310.
14. Kim YA, Wuchty S, Przytycka TM (2011) Identifying causal genes and
dysregulated pathways in complex diseases. PLoS Comput Biol 7: e1001095.
15. Torkamani A, Schork NJ (2009) Identification of rare cancer driver mutations by
network reconstruction. Genome Res 19: 1570–1578.
16. Kar G, Gursoy A, Keskin O (2009) Human cancer protein-protein interaction
network: a structural perspective. PLoS Comput Biol 5: e1000601.
17. Huang YJ, Hang D, Lu LJ, Tong L, Gerstein MB, et al. (2008) Targeting the
human cancer pathway protein interaction network by structural genomics. Mol
Cell Proteomics 7: 2048–2060.
18. Tyagi M, Hashimoto K, Shoemaker BA, Wuchty S, Panchenko AR (2012)
Large-scale mapping of human protein interactome using structural complexes.
EMBO Rep 13: 266–271.
19. Kuzu G, Keskin O, Gursoy A, Nussinov R (2012) Constructing structural
networks of signaling pathways on the proteome scale. Curr Opin Struct Biol 22:
367–377.
20. Wang X, Wei X, Thijssen B, Das J, Lipkin SM, et al. (2012) Three-dimensional
reconstruction of protein networks provides insight into human genetic disease.
Nat Biotechnol 30: 159–164.
21. Schuster-Bockler B, Bateman A (2008) Protein interactions in human genetic
diseases. Genome Biol 9: R9.
22. Teng S, Madej T, Panchenko A, Alexov E (2009) Modeling effects of human
single nucleotide polymorphisms on protein-protein interactions. Biophys J 96:
2178–2188.
23. David A, Razali R, Wass MN, Sternberg MJ (2012) Protein-protein interaction
sites are hot spots for disease-associated nonsynonymous SNPs. Hum Mutat 33:
359–363.
24. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, et al. (2002)
The WHO classification of tumors of the nervous system. J Neuropathol Exp
Neurol 61: 215–225; discussion 226–219.
25. Network TCGAR (2008) Comprehensive genomic characterization defines
human glioblastoma genes and core pathways. Nature 455: 1061–1068.
26. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated
genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
27. Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the
evolution of gliomas. Cancer Sci 100: 2235–2241.
28. Kawashima S, Pokarowski P, Pokarowska M, Kolinski A, Katayama T, et al.
(2008) AAindex: amino acid index database, progress report 2008. Nucleic Acids
Res 36: D202–205.
29. Radivojac P, Baenziger PH, Kann MG, Mort ME, Hahn MW, et al. (2008)
Gain and loss of phosphorylation sites in human cancer. Bioinformatics 24:
i241–247.
30. Hornbeck PV, Chabra I, Kornhauser JM, Skrzypek E, Zhang B (2004)
PhosphoSite: A bioinformatics resource dedicated to physiological protein
phosphorylation. Proteomics 4: 1551–1561.
31. Dinkel H, Chica C, Via A, Gould CM, Jensen LJ, et al. (2011) Phospho.ELM: a
database of phosphorylation sites–update 2011. Nucleic Acids Res 39: D261–
267.
32. Gnad F, Gunawardena J, Mann M (2011) PHOSIDA 2011: the posttransla-
tional modification database. Nucleic Acids Res 39: D253–260.
33. Xue Y, Liu Z, Cao J, Ma Q, Gao X, et al. (2011) GPS 2.1: enhanced prediction
of kinase-specific phosphorylation sites with an algorithm of motif length
selection. Protein Eng Des Sel 24: 255–260.
34. Nishi H, Hashimoto K, Panchenko AR (2011) Phosphorylation in protein-
protein binding: effect on stability and function. Structure 19: 1807–1815.
35. Bogan AA, Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol
Biol 280: 1–9.
36. Tyagi M, Shoemaker BA, Bryant SH, Panchenko AR (2009) Exploring
functional roles of multibinding protein interfaces. Protein Sci 18: 1674–1683.
37. Tuncbag N, Gursoy A, Keskin O (2009) Identification of computational hot
spots in protein interfaces: combining solvent accessibility and inter-residue
potentials improves the accuracy. Bioinformatics 25: 1513–1520.
38. Wei Q, Wang L, Wang Q, Kruger WD, Dunbrack RL, Jr. (2010) Testing
computational prediction of missense mutation phenotypes: functional charac-
terization of 204 mutations of human cystathionine beta synthase. Proteins 78:
2058–2074.
39. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, et al. (2009) Cancer-
associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739–744.
40. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, et al. (2009) Glioma-derived mutations
in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Science 324: 261–265.
41. Xu X, Zhao J, Xu Z, Peng B, Huang Q, et al. (2004) Structures of human
cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-
regulatory mechanism of activity. J Biol Chem 279: 33946–33957.
42. Arac D, Boucard AA, Ozkan E, Strop P, Newell E, et al. (2007) Structures of
neuroligin-1 and the neuroligin-1/neurexin-1 beta complex reveal specific
protein-protein and protein-Ca2+ interactions. Neuron 56: 992–1003.
43. Dean C, Scholl FG, Choih J, DeMaria S, Berger J, et al. (2003) Neurexin
mediates the assembly of presynaptic terminals. Nat Neurosci 6: 708–716.
44. Asleson EN, Livingston DM (2003) Investigation of the stability of yeast rad52
mutant proteins uncovers post-translational and transcriptional regulation of
Rad52p. Genetics 163: 91–101.
45. Dong W, Feng L, Xie Y, Zhang H, Wu Y (2011) Hypermethylation-mediated
reduction of LMX1A expression in gastric cancer. Cancer Sci 102: 361–366.
46. Robson EJ, He SJ, Eccles MR (2006) A PANorama of PAX genes in cancer and
development. Nat Rev Cancer 6: 52–62.
47. Xu HE, Rould MA, Xu W, Epstein JA, Maas RL, et al. (1999) Crystal structure
of the human Pax6 paired domain-DNA complex reveals specific roles for the
linker region and carboxy-terminal subdomain in DNA binding. Genes Dev 13:
1263–1275.
48. Xie X, Gu Y, Fox T, Coll JT, Fleming MA, et al. (1998) Crystal structure of
JNK3: a kinase implicated in neuronal apoptosis. Structure 6: 983–991.
49. Sharan R, Ideker T (2006) Modeling cellular machinery through biological
network comparison. Nat Biotechnol 24: 427–433.
50. Shoemaker BA, Zhang D, Thangudu RR, Tyagi M, Fong JH, et al. (2010)
Inferred Biomolecular Interaction Server–a web server to analyze and predict
protein interacting partners and binding sites. Nucleic Acids Res 38: D518–524.
51. Shoemaker BA, Zhang D, Tyagi M, Thangudu RR, Fong JH, et al. (2012) IBIS
(Inferred Biomolecular Interaction Server) reports, predicts and integrates
multiple types of conserved interactions for proteins. Nucleic Acids Res 40:
D834–840.
52. Wang J, Li M, Wang H, Pan Y (2011) Identification of Essential Proteins Based
on Edge Clustering Coefficient. IEEE/ACM Trans Comput Biol Bioinform.
53. Stitziel NO, Kiezun A, Sunyaev S (2011) Computational and statistical
approaches to analyzing variants identified by exome sequencing. Genome Biol
12: 227.
54. Vitkup D, Sander C, Church GM (2003) The amino-acid mutational spectrum
of human genetic disease. Genome Biol 4: R72.
55. Brock K, Talley K, Coley K, Kundrotas P, Alexov E (2007) Optimization of
electrostatic interactions in protein-protein complexes. Biophys J 93: 3340–3352.
56. Selzer T, Albeck S, Schreiber G (2000) Rational design of faster associating and
tighter binding protein complexes. Nat Struct Biol 7: 537–541.
57. Jonsson PF, Bates PA (2006) Global topological features of cancer proteins in the
human interactome. Bioinformatics 22: 2291–2297.
58. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, et al. (2007) The human
disease network. Proc Natl Acad Sci U S A 104: 8685–8690.
59. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M (2007) The importance of
bottlenecks in protein networks: correlation with gene essentiality and expression
dynamics. PLoS Comput Biol 3: e59.
60. Cui Q, Ma Y, Jaramillo M, Bari H, Awan A, et al. (2007) A map of human
cancer signaling. Mol Syst Biol 3: 152.
61. Wu G, Feng X, Stein L (2010) A human functional protein interaction network
and its application to cancer data analysis. Genome Biol 11: R53.
62. Croft D, O’Kelly G, Wu G, Haw R, Gillespie M, et al. (2011) Reactome: a
database of reactions, pathways and biological processes. Nucleic Acids Res 39:
D691–697.
63. Ceol A, Chatr Aryamontri A, Licata L, Peluso D, Briganti L, et al. (2010)
MINT, the molecular interaction database: 2009 update. Nucleic Acids Res 38:
D532–539.
64. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al.
(2009) Human Protein Reference Database–2009 update. Nucleic Acids Res 37:
D767–772.
65. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from
crystalline state. J Mol Biol 372: 774–797.
66. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, et al. (2008) The
Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum
Genet Chapter 10: Unit 10 11.
67. Petrey D, Xiang Z, Tang CL, Xie L, Gimpelev M, et al. (2003) Using multiple
structure alignments, fast model building, and energetic analysis in fold
recognition and homology modeling. Proteins 53 Suppl 6: 430–435.
68. Ponder JW (1999) TINKER-software tools for molecular design: St. Luis:Wa-
shington University.
69. Xiang Z, Honig B (2001) Extending the accuracy limits of prediction for side-
chain conformations. J Mol Biol 311: 421–430.
70. Zhang Y (2009) Protein structure prediction: when is it useful? Curr Opin Struct
Biol 19: 145–155.
71. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of
spatial restraints. J Mol Biol 234: 779–815.
72. Teng S, Srivastava AK, Schwartz CE, Alexov E, Wang L (2010) Structural
assessment of the effects of amino acid substitutions on protein stability and
protein protein interaction. Int J Comput Biol Drug Des 3: 334–349.
73. Zhang Z, Teng S, Wang L, Schwartz CE, Alexov E (2010) Computational
analysis of missense mutations causing Snyder-Robinson syndrome. Hum Mutat
31: 1043–1049.
74. Guerois R, Nielsen JE, Serrano L (2002) Predicting changes in the stability of
proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol
320: 369–387.
Cancer Mutations, Protein Binding and Networks
PLOS ONE | www.plosone.org 10 June 2013 | Volume 8 | Issue 6 | e66273
